You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Chromosomal aberration detection in FFPE tissue using proximity ligation sequencing
SBC: PHASE GENOMICS, INC. Topic: NCIABSTRACT The detection of chromosomal aberrations is a frontline diagnostic for the spectrum of blood neoplasms. Chromosomal aberrations, such as translocations, inversions, deletions and insertions, have been historically identified using cytogenetic methods or more recently through application of long read sequencing or optical mapping technologies. These methods have been less applicable in sol ...
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Small Molecule MYC Degraders as Novel Cancer Therapeutic Agents
SBC: Stemsynergy Therapeutic Topic: 102PROJECT SUMMARY/ABSTRACT The MYC family proteins are comprised of three paralogs termed c-myc, N-myc, and L-myc. The MYC proteins play a fundamental role in cell proliferation and oncogenesis by regulating cellular processes such as gene transcription, protein translation, cell cycle progression, and cell death. While N-myc and L-myc drive oncogenesis in a small number of cancer types, the require ...
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Preclinical Development of a Novel eNAMPT-Neutralizing mAb for Pulmonary Hypertension
SBC: AQUALUNG THERAPEUTICS, CORP Topic: NHLBIABSTRACT Pulmonary arterial hypertension (PAH) is a fatal disease (without curative therapies) that is critically influenced by dysregulated inflammatory pathways. This A1 R42 Fast Track STTR application focuses on eNAMPT (extra- cellular nicotinamide phosphoribosyltransferase) as a novel, highly attractive PAH target. Aqualung Therapeutics has developed a humanized eNAMPT-neutralizing mAb, ALT-10 ...
STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Multispectral Sensor for Chemical Composition Analysis of Ultrafine Aerosols in Air Quality Assessment
SBC: SPECTREE INC. Topic: RProject SummaryWe propose developing and validating a novel platform technology that combines the collection and chemical analysis of ultrafine particles using an in-situ multispectral technique. The sample, collected directly onto the analysis substrate, is analyzed via excitation-emission matrix (EEM) spectroscopy. This approach will be validated against laboratory combustion-generated aerosols, ...
STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Apto-Ankle: Passive, Compliant Ankle with Enhanced Energy Storage and Return in Gait
SBC: ORTHOCARE INNOVATIONS LLC Topic: NICHDPROJECT SUMMARY The Apto-Ankle project will create a novel low-cost, lightweight, unpowered passive compliant ankle that addresses the weaknesses of currently marketed hydraulic passive ankles by combining +/-10° of plantar and dorsiflexion with a gait dependent toe lock to provide energy storage and return, all without use of microprocessors or powered components. Appropriate for DMERC K-2 and K ...
SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Inter-alpha Inhibitors in Experimental Necrotizing Enterocolitis
SBC: PROTHERA BIOLOGICS, INC. Topic: NICHDNecrotizing enterocolitis (NEC) is a devastating acute inflammatory condition of the gastrointestinal tract resulting in intestinal necrosis, systemic sepsis and multi-system organ failure found mostly in infants born prematurely. Despite modern medical advances in the past decade, the etiology remains elusive and morbidity and mortality are still unacceptably high. It has been concluded that the ...
SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Development of an electrical impedance myography (EIM) vaginal device for the evaluation of pelvic skeletal muscles
SBC: BOLD TYPE LLC Topic: NICHD1 Abstract2 Bold Type is developing the “SenseWand”, a wireless pelvic floor diagnostic system (device and app)3 to evaluate pelvic floor muscle health using electrical impedance myography (EIM). PFDs are complex4 conditions (e.g. pelvic organ prolapse, stress urinary incontinence, high tone pelvic floor dysfunction) that impact5 millions of women worldwide. It is estimated that PFDs will affe ...
SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Modulation of Protein S-nitrosylation Signaling as a Potential Therapeutic Breakthrough in Rheumatoid Arthritis
SBC: GSNO THERAPEUTICS, INC. Topic: NIAMSPROJECT SUMMARY Rheumatoid arthritis (RA) is a prevalent autoimmune disease of the joints that involves autoimmunity, B and T cell infiltration, mitochondrial dysfunction, ECM degradation, oxidative stress and inflammation, that ultimately lead to cartilage destruction and bone reabsorption. Oxidative stress is a hallmark of RA: reactive oxygen species (ROS) inflict direct damage via the oxidation ...
SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Inter-alpha Inhibitors in Hypoxic-Ischemic Brain Injury
SBC: PROTHERA BIOLOGICS, INC. Topic: 105Perinatal brain injury resulting in mental retardation and cerebral palsy is the most severe disability in children and affects 40-148 in preterm and 1–2/1000 in full term infants. This places a huge burden on society, emphasizing the critical need for improved prevention/treatment strategies to decrease perinatal brain injury. Hypothermia (HT) is the only FDA approved therapy to attenuate brain ...
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
SARS-CoV-2 vaccines based on RBDs with engineered glycosylation sites
SBC: EMMUNE INC Topic: RWe are developing vaccine antigens for SARS-CoV-2 that focus the antibody response onto neutralizing epitopes in the receptor binding domain (RBD) of the viral Spike (S) protein. Booster antigens derived from variants of SARS-CoV-2 would especially benefit from being limited to the RBD, due to the preponderance of conserved but non-neutralizing epitopes in the full-length S protein. However, RBD-o ...
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health